IL-12 Gene and in Vivo Electroporation-Mediated Plasmid DNA Vaccine Therapy in Patients With Merkel Cell Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

January 3, 2012

Primary Completion Date

April 10, 2015

Study Completion Date

April 10, 2015

Conditions
Merkel Cell Carcinoma
Interventions
BIOLOGICAL

Tavokinogene Telseplasmid (tavo)

Patients received intratumoral injection(s) of tavo.

DEVICE

OncoSec Medical System (OMS)

Electroporation via OMS was performed immediately following intratumoral injection of tavo. A sterile applicator containing 6 stainless steel electrodes arranged in a circle were placed around the tumor. The applicator was connected to the OMS power supply and six pulses were administered to each tumor lesion at the approximate point of tavo injection.

Trial Locations (1)

98109

Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

OncoSec Medical Incorporated

INDUSTRY

NCT01440816 - IL-12 Gene and in Vivo Electroporation-Mediated Plasmid DNA Vaccine Therapy in Patients With Merkel Cell Cancer | Biotech Hunter | Biotech Hunter